B2M and cancer: Consistently, both genetic or pharmacologic inhibition of EZH2 enhanced H-2Kb and β2M expression (Supplemental Figure 7, E–H) and reduced H3K27me3 modification levels on H2K1 and B2m promoter region in RM1 and MC38 cancer cells (Supplemental Figure 7I).